Abstract
We investigated the course of 54 patients presenting with primary central nervous system lymphoma, who were treated in daily practice. The patients were treated with chemotherapy and/or radiotherapy and/or intrathecal chemotherapy. At a median follow-up period of 23 months (range 1-71), median relapse-free survival (RFS) and overall survival (OS) were not reached. Estimated 2-year RFS and OS rates were 42% and 48%, respectively. Ten relapsed PCNSL patients underwent ASCT. Complete remission rate of these patients was 40%, with 20% treatment-related mortality. Estimated 2-year RFS and OS rates were 37% and 40%, respectively. The prognosis of patients with PCNSL, who received off-study treatment, is still dismal.
References
Sep 1, 1994·Neurology·D H LachanceS C Schold
Sep 1, 1995·Cancer Treatment Reviews·A J FerreriE Villa
Jan 1, 1997·Bone Marrow Transplantation·A StamatoullasH Tilly
Feb 9, 2002·Annals of Neurology·Ulrich HerrlingerMichael Weller
Dec 19, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lisa M DeAngelisUNKNOWN Radiation Therapy Oncology Group Study 93-10
Mar 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tracy BatchelorRegina Priet
Nov 5, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hendrik PelsUwe Schlegel
Jan 12, 2005·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·M BellinzonaM Saini
Jun 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lauren E AbreyUNKNOWN International Primary CNS Lymphoma Collaborative Group
Dec 13, 2005·Cancer·Beela S MathewStuart A Grossman
Nov 23, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lauren E AbreyLisa M DeAngelis
Dec 23, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M MontemurroG Dölken
Apr 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carole SoussainUNKNOWN Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire
Oct 15, 2008·Leukemia & Lymphoma·James RubensteinStefania Pittaluga
Nov 21, 2008·Leukemia & Lymphoma·Andrés J M FerreriMichele Reni
Sep 22, 2009·Lancet·Andrés J M FerreriUNKNOWN International Extranodal Lymphoma Study Group (IELSG)
Oct 26, 2010·The Lancet Oncology·Eckhard ThielMichael Weller
Feb 9, 2011·Blood·Elias CampoElaine S Jaffe
Aug 6, 2011·Leukemia·M DeckertL M DeAngelis
Mar 14, 2012·Best Practice & Research. Clinical Haematology·Andrés J M Ferreri, Emerenziana Marturano
Jul 17, 2012·Hematology/oncology Clinics of North America·Priscilla K Brastianos, Tracy T Batchelor
Apr 10, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James L RubensteinLawrence D Kaplan